» Breast Cancer

Breast Cancer


AAMC Breast Trials

KAITLIN: A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER2-positive Primary Breast Cancer (NCT01966471)
The purpose of this clinical trial is to evaluate the efficacy and safety of Kadcyla together with Perjeta compared to Herceptin together with Perjeta and a taxane as treatment after surgery in patients with HER2-positive breast cancer.
Website: http://www.clinicaltrials.gov/ct2/show/study/NCT01966471?term=BO28407&rank=1
Principal Investigator: Dr. Carol Tweed
Research Staff: Emily Ross, CCRC – (443)481-4392
Venita Alston Crawford, RN – (443)481-4393

Does Breast Tumor Heterogeneity Necessitate Additional HER2 Testing on the Surgical Specimens?
Breast cancer biomarkers are usually performed on core needle biopsy (CNB) specimens and are not routinely repeated on surgical specimens (SS). However, preliminary data suggests that testing these biomarkers, on SS when compared to CNB samples can lead to different results. The aim of this study is to identify a group of women with invasive breast cancer who may benefit from additional HER2 testing on their SS to ensure that areas of HER2 amplification are not missed.  Another aim is to determine whether further HER2 testing on the SS in select patients would lead to changes in breast cancer treatment options.
Website:  http://www.cancer.gov/clinicaltrials/search/view?cdrid=759838&version=HealthProfessional&protocolsearchid=12731574
Principle Investigator:  Lorraine Tafra,  MD
Research Coordinator: Kristen Sawyer,  MS,  CCRA (443-481-5749)

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
The primary objective of this study is to compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR) positive and HER2-negative breast cancer
Website: http://clinicaltrials.gov/ct2/show/NCT01674140?term=S1207&rank=1
Principal Investigator:  Carol Tweed, M.D.
Research Coordinators:  Emily Ross, CCRC  (443) 481-4392
Venita Alston Crawford, RN  (443)481-4393

E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer. Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast cancer live more comfortably. It is not yet known whether early surgery is more effective than palliative therapy for advanced breast cancer,
Websitehttp://clinicaltrials.gov/ct2/show/NCT01242800?term=E+2108+BREAST+MARYLAND&rank=1
Principal Investigator:
Robert Buras, MD
Research Coordinator: Kristen Sawyer, CCRA (443)481-5749

Tissue and Blood Library Establishment for Molecular, Biochemical and Histologic Study of Breast Disease
The purpose of this clinical trial is to collect breast tissue, lymph node tissue, blood samples and data (information) about patient health for use in current and future research studies on breast cancer and breast diseases.  It is also possible that this blood and tissue may be used in research to learn more about other types of cancer and other diseases. The research that may be done with the blood or tissue collected is not designed specifically to help the patient from whom it is collected. This study is for patients that are scheduled to have part of all of their breast tissue surgically removed as part of their clinical care.
Principal Investigator: Dr. Lorraine Tafra – (443)481-5300
Research Coordinator:

Our Studies